Valueadd others a few of my thoughts;
This could be too much (IP in our pipeline) to then have it all sold out to only one big pharma.
If this science is as valuable as our management team have been hinting ( I think it probably is) and this technology over time becomes and forms the foundations of most cancer treatments amongst a wide range of cancer types, replacing many if not all T-cell vaccines which are currently in use, then the thought of selling it all to just one player could / would / may/ put that one company that buys out IMU in a largely advantageous monopolistic position compared with its peers.
In my opinion for the sake of fair competition and the continued development of this technology platform it would be better to farm out different types of vaccines for different types of cancers etc to various (not one) big pharma under a number of individualised licencing agreements, with small upfront payments but lucrative ongoing royalties on sales.
Such a roll out would help create multiple big pharma customers without giving a huge monopolistic advantage to just one player becoming able to clean up the whole B-Cell cancer vaccine market to itself.
I think the IMU board will know that in such regards they have have a moral responsibility that when it comes to deal making, that could should all IP is given to one company create such a huge advantage to that one company that it could become some sort of hideous uncompetitive monster company controlling the whole life changing B-cell vaccine platform which forms the foundation of nearly all cancer treatments.
Surely more profitable for IMU and nicer for all that multiple big pharmers get little bits each.
fp
(20min delay)
